MA
TBPH icon

MUFG Americas’s Theravance Biopharma TBPH Stock Holding History

MUFG Americas’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-329
Closed -$6K – 1191
2016
Q1 		$6K Buy
+329
New +$5.38K ﹤0.01% 915

Other funds holding TBPH

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

MUFG Americas's TBPH Position: Q2 2016 in Review

MUFG Americas sold out of Theravance Biopharma (TBPH) in Q2 2016, closing a stake of 329 shares — an estimated $6K sold.

MUFG Americas first reported a position in TBPH in Q1 2016 and held it in 1 quarter. The position peaked at $6K in Q1 2016. 98 funds tracked by Wall St. Rank hold TBPH as of Q2 2016.

  • MUFG Americas reported no remaining Theravance Biopharma position as of Q2 2016 after selling out during the quarter.
  • MUFG Americas sold 329 Theravance Biopharma shares in Q2 2016, an estimated $6K.
  • MUFG Americas first reported a position in Theravance Biopharma in Q1 2016 and held it in 1 quarter.
  • MUFG Americas's Theravance Biopharma position peaked at $6K in Q1 2016.
  • 98 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2016.

Based on MUFG Americas's 13F filing for Q2 2016, filed 8 Aug 2016.